ValuEngine Upgrades Revance Therapeutics (NASDAQ:RVNC) to “Hold”

ValuEngine upgraded shares of Revance Therapeutics (NASDAQ:RVNC) from a sell rating to a hold rating in a report published on Thursday morning, ValuEngine reports.

A number of other analysts have also recently commented on RVNC. BidaskClub upgraded Revance Therapeutics from a sell rating to a hold rating in a research report on Wednesday, July 31st. Mizuho reiterated a buy rating and set a $37.00 price objective on shares of Revance Therapeutics in a research report on Wednesday, April 24th. Finally, Barclays began coverage on Revance Therapeutics in a research report on Tuesday, June 11th. They set an overweight rating and a $28.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $33.09.

Revance Therapeutics stock traded down $0.52 during midday trading on Thursday, reaching $11.75. 8,551 shares of the company were exchanged, compared to its average volume of 368,603. The firm has a market capitalization of $540.00 million, a P/E ratio of -3.11 and a beta of 1.00. The company’s 50-day moving average is $12.23. Revance Therapeutics has a 1 year low of $10.37 and a 1 year high of $29.90. The company has a quick ratio of 8.13, a current ratio of 8.13 and a debt-to-equity ratio of 0.13.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.02). The company had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $1.85 million. Revance Therapeutics had a negative return on equity of 75.31% and a negative net margin of 3,745.97%. On average, sell-side analysts expect that Revance Therapeutics will post -3.63 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. FNY Investment Advisers LLC purchased a new stake in Revance Therapeutics in the 2nd quarter valued at about $37,000. Edge Wealth Management LLC grew its holdings in Revance Therapeutics by 550.0% in the 1st quarter. Edge Wealth Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 2,750 shares during the period. BNP Paribas Arbitrage SA purchased a new stake in Revance Therapeutics in the 1st quarter valued at about $125,000. Legal & General Group Plc grew its holdings in Revance Therapeutics by 21.7% in the 4th quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 1,150 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Revance Therapeutics in the 1st quarter valued at about $170,000. Institutional investors own 94.81% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

See Also: Hedge Funds

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.